Call us today: +1 (304) 470-2225
English
You can use WPML or Polylang and their language switchers in this area.
Report Store

Artificial Intelligence (AI) in Drug Development (Pharma & Biotech): Competition Analysis 2024

$3,500.00$7,000.00

Innovation And Growth Dynamics: Analyzing Key Companies, Business Models, And Collaborative Ventures In Ai-enhanced Drug Development

  • Strategic Analysis of AI-Driven Drug Discovery
  • Geographical Impact on Biotech Innovations
  • Top 10 Companies Business Models & Strategies’
  • Mergers, Acquisitions, and Market Consolidation Trends
  • Assessment of Clinical Pipeline Robustness
  • Intellectual Property Strategy
  • AI Technologies and Drug Development Efficiency
  • Investment Recommendations Based on Current Trends
Wishlist

Description

The report, “Artificial Intelligence (AI) in Drug Development (Pharma & Biotech): Competition Analysis 2024“, brings to light the significant strides and investment trends in AI-driven drug discovery, particularly focusing on the top 10 companies transforming the pharmaceutical and biotech industries. This comprehensive analysis, combining data-driven insights and expert evaluations, highlights the strategic shifts and geographic influences shaping the future of drug discovery.

This groundbreaking analysis, based on detailed research and data analytics, shines a spotlight on the dynamic AI-driven drug discovery landscape, focusing on the top 10 companies revolutionizing the pharmaceutical and biotech industries with their innovative approaches and significant investments totaling $4.7 billion.

Artificial Intelligence in Drug Development: 2024 Industry Analysis Report Findings:

  • Strategic Shift: A significant trend is observed in companies focusing on complex biological molecules for AI-driven drug discovery, presenting a unique investment opportunity. This shift diversifies from the traditional focus on small molecules.
  • Geographic Advantage: The United States emerges as a leader, boasting the highest number of AI drug discovery companies and investments, providing a robust environment for investors.
  • Acquisition Dominance and Market Leadership: Companies like Recursion, Nimbus Therapeutics, and Exscientia, which hold a dominant 80.65% share in deal sizes, underscore their market leadership through strategic acquisitions and collaborations.
  • Pipeline Potential: Neumora and Insilico Medicine stand out for their advanced clinical trial pipelines and diverse drug portfolios, marking them as attractive investment avenues.
  • IP Dominance: BenevolentAI’s extensive patent filings demonstrate a strong IP strategy. Recursion, with the highest number of granted patents, showcases its prowess in drug discovery and preclinical studies.
  • Technology Leadership: The use of AI technologies by Recursion and Insilico Medicine to refine and expedite drug development stages sets new industry benchmarks in efficiency and effectiveness.

Top AI Pharma Companies: Investment Recommendations

  • Diversify Portfolio: Investments in companies specializing in complex biological molecules can offer diversified risks and access to emerging opportunities.
  • Focus on U.S. Companies: With a significant concentration in the United States, these companies present potential growth opportunities.
  • Target Acquirers: Companies like Recursion and Exscientia with a strong acquisition and collaboration history may offer promising investment prospects.
  • Pipeline Evaluation: Consider companies with advanced drug pipelines for long-term growth potential.

Investment Trends in AI-Enhanced Pharmaceutical Development

  • Exscientia leads with approximately $830 million in total investments, thanks to its advanced AI technologies and strategic business model.
Graph showing AI Pharma Investment Trends
Investment Trends in AI drug Development-Enhanced Pharmaceutical Development– Mellalta Meets
  • Neumora, Nimbus Therapeutics, and Recursion follow closely, each securing around $600 million, underlining their solid positions in the industry.
  • The U.S. dominates with 60% of these companies, indicating substantial investment inflows. The U.K. and Canada, along with Hong Kong, also emerge as significant players.

Top AI Pharma Companies: Collaborations Deals:

  • Clinical Development Deals: A major portion of the deals (63 out of 92) focused on drug/clinical development.
  • Expanded Agreements and Acquisitions: Included 11 expanded agreement deals and 10 company acquisitions.
  • A steady rise in joint ventures, new company launches, co-foundings, co-developments, and co-commercializations is noted.

This report is pivotal for stakeholders in the pharma and biotech industries, investors, and competitors, offering a detailed overview of the AI revolution in drug discovery and development. It serves as a strategic guide to understand and navigate the rapidly evolving landscape of AI in pharma.

Top AI Pharma Companies: Targets and Therapy Areas Pipeline Strategies:

    • Targets in AI-Driven Drug Discovery: The landscape of AI-enhanced drug discovery is marked by a diverse range of biological targets, indicating a focused approach towards addressing specific pathways and mechanisms in disease treatment. Notable among these are small molecule targets, with companies like Exscientia and Nimbus Therapeutics leading the way in developing bispecific molecules and adenosine A2A antagonists, particularly in the realm of immuno-oncology. Other significant targets include serotonin 5-HT1A receptor agonists for neurological conditions and various kinase inhibitors like CDK7 and Tyk2, pivotal in regulating cellular processes. The exploration of targets such as Casein kinase 1 delta and glucocerebrosidase by Neumora showcases an interest in neurodegenerative diseases, while Nimbus Therapeutics’ focus on Acetyl-CoA Carboxylase (ACC) for metabolic disorders like NASH and HCC highlights the expansion into metabolic enzymatic pathways. This variety in targets underscores the AI-driven strategy to develop more precise and effective therapies across a spectrum of diseases.
    • Therapy Areas in AI-Enhanced Drug Development: The therapy areas being targeted in AI-driven drug discovery collaborations span a wide range of medical conditions, reflecting the expansive potential of AI in healthcare. Oncology is a predominant focus, with numerous partnerships like those of Exscientia, Recursion, and Benevolent AI aiming to develop novel cancer treatments. This is complemented by a significant emphasis on immunology, with collaborations seeking to innovate in autoimmune disorders and other immune-related conditions. Neurodegenerative diseases are also a key area, as evidenced by Neumora’s collaborations, targeting conditions like Alzheimer’s and Parkinson’s disease. The interest in rare diseases and metabolic disorders is evident in the efforts of companies like Rallybio and Nimbus Therapeutics, focusing on treatments for less common but impactful health issues. Additionally, CNS disorders and cardiovascular, renal, and pulmonary conditions are also being targeted, showcasing the broad spectrum of therapeutic areas that AI-driven drug development is poised to revolutionize.

About Mellalta Meets:

Mellalta Meets specializes in delivering crucial, timely intelligence crucial for navigating the dynamic pharmaceutical industry. Our expertise spans across market access, medical affairs, sales and marketing, digital health, and various therapy areas. We equip your team with expert insights and comprehensive intelligence, ensuring you maintain a competitive edge in the ever-evolving pharmaceutical landscape. Mellalta Meets is your trusted partner in making informed decisions and staying ahead in the complex world of pharmaceuticals.

Additional information

Price

, , ,

Table of Contents

Table of Contents (223 pages)

  1. Executive Summary
    • Overview of the Report’s Key Findings
  2. Report Methodology Overview
    • Approach and Data Sources
  3. Key Analysis (In-Depth Insights and Strategic Assessments)
    • Top 10 AI-Driven Drug Discovery Companies by Investment
      • Detailed Financial Analysis
    • Top 10 AI-Driven Drug Discovery Companies by Country of Origin
      • Geographic Distribution and Influence
    • Acquisitions, Collaborations, and Licensing Deals
      • By Company
      • By Size
      • By Type Per Year
    • Competitive Landscape Analysis
      • By Technology
      • By Molecule Complexity
    • Technology Trends: AI-Based Drug Discovery
      • Current and Future Trends
    • Technology Advancements: AI-Based Biologics Research
      • Innovations and Developments
    • Introduction of AI into Pre-Clinical/Clinical Trials Design
      • Impact and Advancements
    • Current Status of AI Technology Patents
      • By Stage Type
      • By Filing Status
    • Company Pipeline Progress with Interesting Targets
      • Highlighting Notable Drug Candidates
  1. Individual Company Analysis
    • Company 1: Exscientia
      • Company Profile
      • Business Models
      • AI Technologies
      • Patents
      • Pipeline
      • Collaborations
    • Company 2: Neumora
      • Company Profile
      • Business Models
      • AI Technologies
      • Patents
      • Pipeline
      • Collaborations
    • Company 3: Nimbus Therapeutics
      • Company Profile
      • Business Models
      • AI Technologies
      • Patents
      • Pipeline
      • Collaborations
    • Company 4: Recursion
      • Company Profile
      • Business Models
      • AI Technologies
      • Patents
      • Pipeline
      • Collaborations
    • Company 5: Benevolent AI
      • Company Profile
      • Business Models
      • AI Technologies
      • Patents
      • Pipeline
      • Collaborations
    • Company 6: BPGbio
      • Company Profile
      • Business Models
      • AI Technologies
      • Patents
      • Pipeline
      • Collaborations
    • Company 7: Insilico Medicine
      • Company Profile
      • Business Models
      • AI Technologies
      • Patents
      • Pipeline
      • Collaborations
    • Company 8: Schrödinger
      • Company Profile
      • Business Models
      • AI Technologies
      • Patents
      • Pipeline
      • Collaborations
    • Company 9: Deep Genomics
      • Company Profile
      • Business Models
      • AI Technologies
      • Patents
      • Pipeline
      • Collaborations
    • Company 10: Absci
      • Company Profile
      • Business Models
      • AI Technologies
      • Patents
      • Pipeline
      • Collaborations
  1. Contact Us
    • Information for Further Inquiries

Sample Enquiry

A typical mobile number in USA is +1 (555) 555-1234